Emergent BioSolutions is a global life sciences company that develops and manufactures medical products and solutions addressing public health threats, including chemical, biological, radiological, and nuclear threats, as well as emerging infectious diseases and emergency care needs. The company operates through three primary business segments: commercial products (naloxone-based medications sold through retail and government channels), medical countermeasures (vaccines, antivirals, antibodies, and antitoxins sold primarily to the U.S. Government and international health agencies under government contracts), and contract development and manufacturing services for pharmaceutical and biotech customers at facilities in Canada and Maryland. Revenue is generated from product sales and procurement, contract manufacturing services, and non-dilutive government research funding.